Clinical Research and Clinical Trial in Vaccines

  • This study is a randomized, double-blinded, and placebo controlled phase III clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Pvt. Ltd Company. The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental vaccine in healthy adults aged 18~59 Years.

     

    Primary Outcome Measures:

    ·         Protection Indexes of Two Vaccine Doses for Symptomatic COVID-19 (Time Frame: 2 weeks after the second dose of vaccination)

    ·         The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19

     

    Secondary Outcome Measures:

  1. Protection Indexes of One Vaccine Dose For Symptomatic COVID-19 (Time Frame: 2 weeks after the second dose of vaccination)

  • The protection rate of, at least, one dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19 Two weeks after the last dose vaccination.

      2.Protection Indexes of Second Vaccine Dose For Hospitalization, Disease Severity/and Death                           (Time Frame: 2 weeks after the second dose of vaccination)

  • The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against rates of hospitalization, disease severity/and death two weeks after the second dose of vaccination

      3.Protection Indexes of Two Vaccine Doses For SARS-CoV-2 infection  (Time Frame: 2 weeks after the             second dose of vaccination)

  • The protection rate of a two dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed SARS-CoV-2 infection two weeks after the second dose of vaccination

      4.Safety indexes of adverse reactions in 28 days  (Time Frame: 28 days after the second dose of                          vaccination)

  • The incidence of adverse reactions from the day of first vaccination to 28 days after the second dose of vaccination.

  • This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants aged 18 years and older who

Related Conference of Clinical Research and Clinical Trial in Vaccines

September 22-23, 2025

21st Global Biomarkers and Clinical Research Summit

Paris, France
September 25-26, 2025

3rd International Conference on Oral Health and Dentistry

Zurich, Switzerland
October 27-28, 2025

10th Global Summit on Midwifery and Womens Health

Madrid, Spain
October 30-31, 2025

6th International Conferences in COPD & Lung Disease

Paris, France
November 13-14, 2025

11th World Holistic Nursing Conference

Bali, Indonesia
November 13-14, 2025

5th Euro-Global Summit on Probiotics & Nutraceuticals

Paris, France
November 20-21, 2025

6th Global Summit on Public Health

Amsterdam, Netherlands
November 24-25, 2025

4th Global Conference on Aging and Gerontology

Barcelona, Spain
November 24-25, 2025

11th Global Public Health, Occupational Safety and Health Policy

Aix-en-Provence, France
December 04-05, 2025

Innateimmunity

Dubai, UAE
December 17-18, 2025

8th Annual Congress on Wellness and Alternative Healthcare Informatics

Aix-en-Provence, France
December 17-18, 2025

12th World congress on Hospice and Palliative care

Aix-en-Provence, France
December 29-30, 2025

13th International Conference on Hospital Management and Health Care

Amsterdam, Netherlands
January 28-29, 2026

43rd International Conference on Women's Health

Bangkok, Thailand
March 12-13, 2026

8th International Conference on Digital Health

London, UK
April 20-21, 2026

7th Global Summit on Digital Therapeutics

Barcelona, Spain
April 27-28, 2026

8th World Summit on Women's Health and Cancer Awareness

Vancouver, Canada

Clinical Research and Clinical Trial in Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in